Related Experiment Videos
AT1-receptor blocker-based combination therapy in hypertension
1Ludwig Maximilian University Munich, Starnberg, Germany. Peter.Trenkwalder@t-online.de
Insights
A new combination of candesartan cilexetil-hydrochlorothiazide (HCT) offers superior blood pressure control for hypertension patients needing more than monotherapy. This effective and well-tolerated regimen provides sustained antihypertensive effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Nephrology
Background:
- Hypertension remains a global health challenge, with many patients failing to achieve target blood pressure control despite treatment.
- Combination therapy with complementary mechanisms, like angiotensin II receptor blockers (ARBs) and diuretics, is crucial for managing resistant hypertension.
Purpose of the Study:
- To evaluate the efficacy and tolerability of a fixed-dose combination of candesartan cilexetil-hydrochlorothiazide (HCT) 16/12.5 mg in patients with hypertension.
- To compare the antihypertensive effects of candesartan cilexetil-HCT with monotherapy and another ARB-diuretic combination.
Main Methods:
- Clinical trials involving patients with mild-to-moderate and mild, moderate, or severe hypertension.
- Double-blind, randomized studies comparing candesartan cilexetil-HCT 16/12.5 mg against monotherapy and losartan-HCT 50/12.5 mg.
Main Results:
- Candesartan cilexetil-HCT 16/12.5 mg demonstrated significantly greater efficacy than monotherapy in patients with mild-to-moderate hypertension.
- The combination was more effective than losartan-HCT 50/12.5 mg in patients with varying degrees of hypertension.
- Antihypertensive effects of candesartan cilexetil-HCT persisted for up to 48 hours, unlike the rapid decline observed with losartan-HCT.
Conclusions:
- The fixed-dose combination of candesartan cilexetil-HCT 16/12.5 mg offers enhanced efficacy and excellent tolerability for hypertension management.
- This combination represents a new standard of care for patients requiring more than monotherapy for blood pressure control.
Abstract:
Despite an increase in the number of patients treated for hypertension, blood pressure control is achieved in a minority of patients. The use of rational, well-tolerated combination regimens with complementary modes of action, such as an AT1-receptor blocker administered with a low dose of a thiazide diuretic, provides an effective and well-tolerated management strategy for patients who require more than monotherapy to control blood pressure. In clinical trials in patients with mild-to-moderate hypertension, a newly available combination of candesartan cilexetil-hydrochlorothiazide (HCT) 16/12.5 mg was significantly more effective than either monotherapy. This combination was also more effective than losartan-HCT 50/12.5 mg in two double-blind, randomized studies in patients with mild, moderate or severe hypertension. Furthermore, the antihypertensive efficacy of candesartan cilexetil-HCT was evident at up to 48 h following the last dose, while the effect of losartan-HCT declined rapidly during this period. Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy.